Abcon Therapeutics, Inc. is dedicated to the development of first-in-class therapeutics for T-cell mediated diseases and related cancers. The Company’s first product, ATX101, is a fully humanized monoclonal antibody-drug conjugate (ADC) that targets CD6, an established T cell marker. ATX101 has been highly effective in treating preclinical models of T-cell lymphoma (TCL), demonstrating tumor shrinkage and inhibition of tumor metastasis. ATX101 also selectively eliminates activated proliferating T cells and showed efficacy in treating preclinical models of autoimmune uveitis and graft-versus-host disease, both in which activated T cells cause the disease. The National Cancer Institute’s NExT program is partnering with Abcon to carry out the manufacturing and preclinical toxicology, pharmacokinetic and pharmacodynamics work required to advance it into human clinical trials. Based on the limited expression profile of CD6 and the known efficacy of other FDA-approved ADCs targeting different proteins but using the same linker and payload technology, ATX101 is expected to be a safe and effective treatment for aggressive TCL. The pre-clinical efficacy of mouse anti-CD6 ADC, a precursor to ATX101, has also been demonstrated in animal models of autoimmune uveitis and graft versus host disease.